|
E.Yu. Evdokimov, Zh.B. Ponezheva, E.V. Svechnikova, B.M. Gruzdev
Experience with the use of netakimab for the treatment of psoriasis in HIV-infected patients
|
№8 / 2022
|
|
A.A. Khryanin, A.V. Sokolovskaya, V.K. Bocharova
Psoriasis in the perianal area: clinical manifestations, differential diagnosis and therapy
|
№8 / 2022
|
|
M.A. Morzhanaeva (1), E.V. Svechnikova (1, 2), E.V. Shchepkina (3), A.I. Kuznetsov (4)
Application of the diabetes screening questionnaire in patients with psoriasis
|
№4 / 2022
|
|
L.S. Kruglova (1), A.A. Khotko (2), N.S. Rudneva (3)
Are the goals of psoriasis treatment achievable in real clinical practice?
|
№14 / 2021
|
|
L.S. Kruglova, N.O. Pereverzina
The effectiveness of early administration of interleukin-17 blockers in the treatment of axial lesions in psoriatic arthritis
|
№14 / 2021
|
|
E.V. Svechnikova (1, 2)
Review of clinical trials of the IL-23 inhibitor guselkumab. Experience of using genetically engineered biological therapy with guselkumab in a patient with severe arthropathic psoriasis
|
№8 / 2021
|
|
A.S. Zhukov (1), E.R. Zharun (1), M.A. Chaykina (1), V.R. Khairutdinov (1), A.V. Samtsov (1), M.Yu. Krasavin (2), A.V. Garabadzhiu (3)
Evaluation of the safety and tolerability of a topical serine protease inhibitor (Part 2)
|
№8 / 2021
|
|
A.S. Zhukov (1), E.R. Zharun (1), M.A. Chaykina (1), A.A. Chernyshova (2), V.R. Khairutdinov (1), A.V. Samtsov (1), A.V. Garabadzhiu (3)
Determination of the therapeutic efficacy of various concentrations of sivelestat on a laboratory model of psoriasis (Part 1)
|
№8 / 2021
|
|
M.A. Morzhanaeva (1), E.V. Shchepkina (2)
Analysis of anxiety-depressive states of patients with psoriasis and diabetes mellitus
|
№8 / 2021
|
|
K.A. Fomin (1, 2), N.A. Merzlikina (1), S.E. Zhufina (1), E.V. Svechnikova (1, 3)
Longitudinal systemic therapy of plaque psoriasis: a literature review with a case report of use of ixekizumab
|
№8 / 2021
|
|
N.A. Merzlikina (1), E.V. Svechnikova (1, 2), S.E. Zhufina (1)
Modern therapy of psoriasis from the point of view of systemic inflammation: experience of using the drug Efleira
|
№8 / 2021
|
|
S.E. Zhufina (1), K.A. Fomin (1), E.V. Svechnikova (1, 2)
Analysis of comorbid conditions and tolerability of treatment with genetically engineered biological drugs and methotrexate in patients with psoriasis
|
№8 / 2021
|
Русский
